Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

NXP800

Small molecule · Inhibitor of Heat shock factor 1 (HSF1) · developed by Nuvectis Pharma

Phase 1 Most advanced trial (none active)
NVCT Developer
1 Registered trials

What is NXP800?

NXP800 is an orally bioavailable small molecule that inhibits the HSF1 pathway, preventing HSF1-mediated transcription of genes that support tumor proliferation, migration, survival and metastasis. It is being studied in advanced solid tumors and ovarian cancers, including ARID1A-mutated disease.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type
Small molecule
Targets
Heat shock factor 1 (HSF1), ARID1A (biomarker)
Mechanism
Inhibitor of Heat shock factor 1 (HSF1)
Pathways
HSF1-regulated heat shock response, HSF1-mediated transcription
Therapy area
Oncology
Developer
Nuvectis Pharma, Inc. (NVCT)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT05226507 Phase 1 Advanced Solid Tumor Terminated NVCT

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Advanced Solid TumorARID1A Gene MutationOvarian CancerOvarian Clear Cell AdenocarcinomaOvarian Clear Cell CarcinomaOvarian Clear Cell TumorOvarian Endometrioid AdenocarcinomaOvarian Endometrioid Tumor

More from Nuvectis Pharma

Sources

Updated Oct 25, 2026. Something wrong or missing? Report it on the NVCT page.

Follow NVCT, the company behind NXP800

See NVCT's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

NVCT catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.